The anabolic signal that lasts.
IGF-1 (Insulin-like Growth Factor-1) is produced primarily by the liver in response to growth hormone stimulation. It mediates many of GH's anabolic effects — muscle protein synthesis, cellular proliferation, and nutrient partitioning. Native IGF-1 has a very short half-life in the bloodstream.
IGF-1 LR3 is a modified version with an arginine substitution and a 13-amino-acid extension at the N-terminus. This modification reduces its binding to IGF binding proteins, which normally sequester IGF-1 in the circulation. The result is a half-life of 20–30 hours compared to minutes for native IGF-1 — and a much more sustained anabolic signal.
The practical implication: IGF-1 LR3 keeps anabolic signaling active for significantly longer, directing nutrients toward muscle cells and away from fat cells, supporting protein synthesis, and promoting cellular regeneration.
A targeted tool for specific goals.
IGF-1 LR3 is not a first-line protocol. It's an advanced option for patients who are already optimizing other variables — nutrition, training, sleep, and often hormonal baseline — and who have a specific anabolic or body composition goal that warrants its use.
Baseline IGF-1 levels must be measured before prescribing. If your natural IGF-1 is already elevated, this protocol is not appropriate. If it's in normal or low-normal range, there may be room to work with it in the right context.
- Lean muscle mass development
- Improved body composition
- Enhanced recovery from training
- Nutrient partitioning toward muscle
- Cellular regeneration support
Cycled carefully. Monitored closely.
IGF-1 LR3 is typically used in cycles of 4–6 weeks, followed by a break. This is not arbitrary — sustained elevated IGF-1 signaling is associated with risks that make continuous long-term use inappropriate for most patients. Cycling allows the benefits while respecting the biology.
Dosing is individualized based on baseline IGF-1 levels, body weight, and goals. IGF-1 is measured at baseline and monitored during the cycle. This is a protocol where the labs genuinely drive decision-making — not just a formality.
| Phase | Duration | Key Monitoring |
|---|---|---|
| Baseline assessment | Pre-protocol | IGF-1, fasting glucose, full panel |
| Active cycle | 4–6 weeks | Symptom check, glucose |
| Post-cycle break | 4+ weeks | IGF-1 return to baseline |
| Reassessment | Before next cycle | Labs + clinical review |
What you should know
Hypoglycemia is the most important practical risk. IGF-1 has insulin-like activity and can lower blood glucose, particularly if taken without food or in too high a dose. This is why patients are instructed to administer with or shortly after a meal and to monitor for symptoms of low blood sugar.
Joint pain, water retention, and fatigue are possible, particularly at higher doses. The theoretical concern that elevated IGF-1 could promote cancer cell proliferation in susceptible individuals is why this is a physician-supervised, monitored protocol — and why patient selection matters.
Common questions about IGF-1 LR3
GH peptides (like CJC/Ipamorelin) stimulate your pituitary to release GH, which then stimulates IGF-1 production. IGF-1 LR3 acts directly at the IGF-1 receptor level, bypassing the GH step. It's a more direct anabolic signal with a different time course and risk profile.
Prolonged elevation of IGF-1 signaling is associated with potential risks related to cell proliferation. Cycling — using the peptide for a defined period, then stopping — allows the body to return to baseline before the next course. It's how we capture the benefits responsibly.
Potentially, but this is something we evaluate carefully. TRT can affect IGF-1 levels directly, so the baseline labs are especially important. The combination of TRT and IGF-1 LR3 requires thoughtful management.
We review your labs, goals, and health history before recommending any protocol. Available in-person in St. Louis or via secure telehealth.
📅 Request a Consultation →